Avantax Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Avantax Advisory Services's VRTX Position: Q2 2025 in Review
Avantax Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2025, buying an estimated $91.7K and bringing the position to 12,873 shares worth $5.73M. The position accounts for 0.03% of the portfolio, ranked #413.
Avantax Advisory Services first reported a position in VRTX in Q4 2019 and has held it in 17 quarters since. The position peaked at $6.14M in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.
- Avantax Advisory Services held 12,873 shares of Vertex Pharmaceuticals worth $5.73M as of Q2 2025.
- Avantax Advisory Services bought 199 Vertex Pharmaceuticals shares in Q2 2025, an estimated $91.7K.
- Vertex Pharmaceuticals made up 0.03% of Avantax Advisory Services's portfolio in Q2 2025, its #413 holding.
- Avantax Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 17 quarters since.
- Avantax Advisory Services's Vertex Pharmaceuticals position peaked at $6.14M in Q1 2025.
- 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.
Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.